Literature DB >> 21312375

Interactions and phase behavior of a monoclonal antibody.

Rachael A Lewus1, Patricia A Darcy, Abraham M Lenhoff, Stanley I Sandler.   

Abstract

Protein phase behavior is implicated in numerous aspects of downstream processing either by design, as in crystallization or precipitation processes, or as an undesired effect, such as aggregation. An improved understanding of protein phase behavior is, therefore, important for developing rational design strategies for important process steps. This work explores the phase behavior of a monoclonal antibody (mAb), IDEC-152, which exhibits liquid-liquid separation, aggregation, gelation, and crystallization. A systematic study of numerous factors, including the effects of solution composition and pH, has been conducted to explore the phase behavior of this antibody. Phenomena observed include a significant dependence of the cloud point on the cation in sulfate salts and nonmonotonic trends in pH dependence. Additionally, conditions for crystallization of this mAb are reported for the first time. Protein-protein interactions, as determined from the osmotic second virial coefficient, are used to interpret the phase behavior.
Copyright © 2011 American Institute of Chemical Engineers (AIChE).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21312375     DOI: 10.1002/btpr.536

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  14 in total

1.  Phase transitions in human IgG solutions.

Authors:  Ying Wang; Aleksey Lomakin; Ramil F Latypov; Jacob P Laubach; Teru Hideshima; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson; George B Benedek
Journal:  J Chem Phys       Date:  2013-09-28       Impact factor: 3.488

2.  Phase separation in solutions of monoclonal antibodies and the effect of human serum albumin.

Authors:  Ying Wang; Aleksey Lomakin; Ramil F Latypov; George B Benedek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-15       Impact factor: 11.205

3.  A stepwise mechanism for aqueous two-phase system formation in concentrated antibody solutions.

Authors:  Bradley A Rogers; Kelvin B Rembert; Matthew F Poyton; Halil I Okur; Amanda R Kale; Tinglu Yang; Jifeng Zhang; Paul S Cremer
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-23       Impact factor: 11.205

4.  Identification and characterization of host cell protein product-associated impurities in monoclonal antibody bioprocessing.

Authors:  Nicholas E Levy; Kristin N Valente; Leila H Choe; Kelvin H Lee; Abraham M Lenhoff
Journal:  Biotechnol Bioeng       Date:  2013-12-11       Impact factor: 4.530

5.  A comparative study of monoclonal antibodies. 1. Phase behavior and protein-protein interactions.

Authors:  Rachael A Lewus; Nicholas E Levy; Abraham M Lenhoff; Stanley I Sandler
Journal:  Biotechnol Prog       Date:  2014-11-19

6.  Pathological crystallization of human immunoglobulins.

Authors:  Ying Wang; Aleksey Lomakin; Teru Hideshima; Jacob P Laubach; Olutayo Ogun; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson; George B Benedek
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-30       Impact factor: 11.205

Review 7.  Protein aggregation and its impact on product quality.

Authors:  Christopher J Roberts
Journal:  Curr Opin Biotechnol       Date:  2014-08-28       Impact factor: 9.740

8.  Determinants of protein elution rates from preparative ion-exchange adsorbents.

Authors:  James M Angelo; Abraham M Lenhoff
Journal:  J Chromatogr A       Date:  2016-02-17       Impact factor: 4.759

9.  Towards protein crystallization as a process step in downstream processing of therapeutic antibodies: screening and optimization at microbatch scale.

Authors:  Yuguo Zang; Bernd Kammerer; Maike Eisenkolb; Katrin Lohr; Hans Kiefer
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

10.  Protein-protein interactions in dilute to concentrated solutions: α-chymotrypsinogen in acidic conditions.

Authors:  Marco A Blanco; Tatiana Perevozchikova; Vincenzo Martorana; Mauro Manno; Christopher J Roberts
Journal:  J Phys Chem B       Date:  2014-05-21       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.